582 related articles for article (PubMed ID: 16540233)
21. Inhibition of PI3K and MEK: it is all about combinations and biomarkers.
Rexer BN; Ghosh R; Arteaga CL
Clin Cancer Res; 2009 Jul; 15(14):4518-20. PubMed ID: 19584146
[TBL] [Abstract][Full Text] [Related]
22. Anti-vascular endothelial growth factor receptor-1 antagonist antibody as a therapeutic agent for cancer.
Wu Y; Zhong Z; Huber J; Bassi R; Finnerty B; Corcoran E; Li H; Navarro E; Balderes P; Jimenez X; Koo H; Mangalampalli VR; Ludwig DL; Tonra JR; Hicklin DJ
Clin Cancer Res; 2006 Nov; 12(21):6573-84. PubMed ID: 17085673
[TBL] [Abstract][Full Text] [Related]
23. TNF alpha acting on TNFR1 promotes breast cancer growth via p42/P44 MAPK, JNK, Akt and NF-kappa B-dependent pathways.
Rivas MA; Carnevale RP; Proietti CJ; Rosemblit C; Beguelin W; Salatino M; Charreau EH; Frahm I; Sapia S; Brouckaert P; Elizalde PV; Schillaci R
Exp Cell Res; 2008 Feb; 314(3):509-29. PubMed ID: 18061162
[TBL] [Abstract][Full Text] [Related]
24. Curcumin suppresses the paclitaxel-induced nuclear factor-kappaB in breast cancer cells and potentiates the growth inhibitory effect of paclitaxel in a breast cancer nude mice model.
Kang HJ; Lee SH; Price JE; Kim LS
Breast J; 2009; 15(3):223-9. PubMed ID: 19645775
[TBL] [Abstract][Full Text] [Related]
25. Targeting the yin and the yang: combined inhibition of the tyrosine kinase c-Src and the tyrosine phosphatase SHP-2 disrupts pancreatic cancer signaling and biology in vitro and tumor formation in vivo.
Gomes EG; Connelly SF; Summy JM
Pancreas; 2013 Jul; 42(5):795-806. PubMed ID: 23271399
[TBL] [Abstract][Full Text] [Related]
26. Induction of reactive oxygen species renders mutant and wild-type K-ras pancreatic carcinoma cells susceptible to Ad.mda-7-induced apoptosis.
Lebedeva IV; Su ZZ; Sarkar D; Gopalkrishnan RV; Waxman S; Yacoub A; Dent P; Fisher PB
Oncogene; 2005 Jan; 24(4):585-96. PubMed ID: 15580305
[TBL] [Abstract][Full Text] [Related]
27. Broad antitumor activity in breast cancer xenografts by motesanib, a highly selective, oral inhibitor of vascular endothelial growth factor, platelet-derived growth factor, and Kit receptors.
Coxon A; Bush T; Saffran D; Kaufman S; Belmontes B; Rex K; Hughes P; Caenepeel S; Rottman JB; Tasker A; Patel V; Kendall R; Radinsky R; Polverino A
Clin Cancer Res; 2009 Jan; 15(1):110-8. PubMed ID: 19118038
[TBL] [Abstract][Full Text] [Related]
28. Blockade of the extracellular signal-regulated kinase pathway enhances the therapeutic efficacy of microtubule-destabilizing agents in human tumor xenograft models.
Watanabe K; Tanimura S; Uchiyama A; Sakamoto T; Kawabata T; Ozaki K; Kohno M
Clin Cancer Res; 2010 Feb; 16(4):1170-8. PubMed ID: 20145173
[TBL] [Abstract][Full Text] [Related]
29. Anti-tumor effect of honokiol alone and in combination with other anti-cancer agents in breast cancer.
Liu H; Zang C; Emde A; Planas-Silva MD; Rosche M; Kühnl A; Schulz CO; Elstner E; Possinger K; Eucker J
Eur J Pharmacol; 2008 Sep; 591(1-3):43-51. PubMed ID: 18588872
[TBL] [Abstract][Full Text] [Related]
30. Inhibition of protein kinase c-Src reduces the incidence of breast cancer metastases and increases survival in mice: implications for therapy.
Rucci N; Recchia I; Angelucci A; Alamanou M; Del Fattore A; Fortunati D; Susa M; Fabbro D; Bologna M; Teti A
J Pharmacol Exp Ther; 2006 Jul; 318(1):161-72. PubMed ID: 16627750
[TBL] [Abstract][Full Text] [Related]
31. Nonclinical antiangiogenesis and antitumor activities of axitinib (AG-013736), an oral, potent, and selective inhibitor of vascular endothelial growth factor receptor tyrosine kinases 1, 2, 3.
Hu-Lowe DD; Zou HY; Grazzini ML; Hallin ME; Wickman GR; Amundson K; Chen JH; Rewolinski DA; Yamazaki S; Wu EY; McTigue MA; Murray BW; Kania RS; O'Connor P; Shalinsky DR; Bender SL
Clin Cancer Res; 2008 Nov; 14(22):7272-83. PubMed ID: 19010843
[TBL] [Abstract][Full Text] [Related]
32. Sichuan pepper extracts block the PAK1/cyclin D1 pathway and the growth of NF1-deficient cancer xenograft in mice.
Hirokawa Y; Nheu T; Grimm K; Mautner V; Maeda S; Yoshida M; Komiyama K; Maruta H
Cancer Biol Ther; 2006 Mar; 5(3):305-9. PubMed ID: 16418572
[TBL] [Abstract][Full Text] [Related]
33. A potential target associated with both cancer and cancer stem cells: a combination therapy for eradication of breast cancer using vinorelbine stealthy liposomes plus parthenolide stealthy liposomes.
Liu Y; Lu WL; Guo J; Du J; Li T; Wu JW; Wang GL; Wang JC; Zhang X; Zhang Q
J Control Release; 2008 Jul; 129(1):18-25. PubMed ID: 18466993
[TBL] [Abstract][Full Text] [Related]
34. A Src family inhibitor (PP1) potentiates tumor-suppressive effect of connexin 32 gene in renal cancer cells.
Fujimoto E; Sato H; Nagashima Y; Negishi E; Shirai S; Fukumoto K; Hagiwara H; Hagiwara K; Ueno K; Yano T
Life Sci; 2005 Apr; 76(23):2711-20. PubMed ID: 15792837
[TBL] [Abstract][Full Text] [Related]
35. In vitro and in vivo evidence that a combination of lapatinib plus S-1 is a promising treatment for pancreatic cancer.
Komoto M; Nakata B; Nishii T; Kawajiri H; Shinto O; Amano R; Yamada N; Yashiro M; Hirakawa K
Cancer Sci; 2010 Feb; 101(2):468-73. PubMed ID: 19925494
[TBL] [Abstract][Full Text] [Related]
36. Effects of novel retinoic acid metabolism blocking agent (VN/14-1) on letrozole-insensitive breast cancer cells.
Belosay A; Brodie AM; Njar VC
Cancer Res; 2006 Dec; 66(23):11485-93. PubMed ID: 17145897
[TBL] [Abstract][Full Text] [Related]
37. SKI-606, a Src/Abl inhibitor with in vivo activity in colon tumor xenograft models.
Golas JM; Lucas J; Etienne C; Golas J; Discafani C; Sridharan L; Boghaert E; Arndt K; Ye F; Boschelli DH; Li F; Titsch C; Huselton C; Chaudhary I; Boschelli F
Cancer Res; 2005 Jun; 65(12):5358-64. PubMed ID: 15958584
[TBL] [Abstract][Full Text] [Related]
38. Combined Src and aromatase inhibition impairs human breast cancer growth in vivo and bypass pathways are activated in AZD0530-resistant tumors.
Chen Y; Guggisberg N; Jorda M; Gonzalez-Angulo A; Hennessy B; Mills GB; Tan CK; Slingerland JM
Clin Cancer Res; 2009 May; 15(10):3396-405. PubMed ID: 19451593
[TBL] [Abstract][Full Text] [Related]
39. Targeting multiple signaling pathways as a strategy for managing prostate cancer: multifocal signal modulation therapy.
McCarty MF
Integr Cancer Ther; 2004 Dec; 3(4):349-80. PubMed ID: 15523106
[TBL] [Abstract][Full Text] [Related]
40. Inhibition of androgen receptor and Cdc25A phosphatase as a combination targeted therapy in molecular apocrine breast cancer.
Naderi A; Liu J
Cancer Lett; 2010 Dec; 298(1):74-87. PubMed ID: 20605569
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]